SIRAKI 02 Posthoc Analysis.
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 343 participants.
Also called NCT06781294
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 343 participants
- Sponsor
- Registry
-
NCT06781294
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06781294. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-01 (actual); primary completion 2026-11-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SIRAKI 02 Posthoc Analysis.
- Acronym
- OXI-SAFE-CEC
- Condition
- Cardiac Surgery Requiring Cardiopulmonary Bypass
- Condition
- Acute Kidney Injury
- Condition
- Kidney Failure, Acute
- Intervention (Device)
- Extracorporeal Cytokine hemadsorption therapy
- Lead sponsor
- Hospital Universitari de Bellvitge
- Collaborator
- University of Barcelona
- Collaborator
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Collaborator
- Germans Trias i Pujol Hospital
- Collaborator
- Institut d'Investigació Biomèdica de Bellvitge
Record details
- Record id
cardio:ct-nct06781294- Content hash
e7c68ba05cf55865b9d868880943218cb75948e0d18321be2ad0647ca8d115e9